AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
carbidopa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors | 496 | 28860-95-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 2.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 5.30 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.68 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 58 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BMX,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,CHUK,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT1,FLT3,FLT4,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM1,PIM2,PLK1,PRKCD,PRKDC,PTK2,SGK1,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 87 | |||
| kinase-selectivity-class | ACVR2B,ACVRL1,AXL,BMX,BRAF,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1 | 23 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 2, 1975 | FDA | MERCK SHARP DOHME | |
| Oct. 17, 2010 | EMA | Orion Corporation |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Parkinson's disease | 192.36 | 18.99 | 38 | 7358 | 1052 | 90619999 |
| Hallucination | 192.34 | 18.99 | 98 | 7298 | 65861 | 90555190 |
| Dyskinesia | 170.21 | 18.99 | 75 | 7321 | 36459 | 90584592 |
| Tremor | 106.58 | 18.99 | 93 | 7303 | 153080 | 90467971 |
| Hallucination, visual | 96.63 | 18.99 | 44 | 7352 | 23048 | 90598003 |
| Fall | 82.99 | 18.99 | 144 | 7252 | 481666 | 90139385 |
| Ileus | 64.43 | 18.99 | 30 | 7366 | 16516 | 90604535 |
| Drug interaction | 61.62 | 18.99 | 93 | 7303 | 276360 | 90344691 |
| Product complaint | 60.52 | 18.99 | 27 | 7369 | 13473 | 90607578 |
| Vascular encephalopathy | 56.39 | 18.99 | 13 | 7383 | 757 | 90620294 |
| Gambling disorder | 55.00 | 18.99 | 14 | 7382 | 1238 | 90619813 |
| Dementia | 45.98 | 18.99 | 27 | 7369 | 23834 | 90597217 |
| Parkinsonism | 41.21 | 18.99 | 21 | 7375 | 14044 | 90607007 |
| Muscle rigidity | 40.87 | 18.99 | 21 | 7375 | 14288 | 90606763 |
| Confusional state | 40.50 | 18.99 | 94 | 7302 | 386111 | 90234940 |
| Abnormal behaviour | 39.43 | 18.99 | 24 | 7372 | 22604 | 90598447 |
| Aortic valve incompetence | 38.76 | 18.99 | 16 | 7380 | 6608 | 90614443 |
| Orthostatic hypotension | 38.67 | 18.99 | 30 | 7366 | 41797 | 90579254 |
| Delusion | 38.63 | 18.99 | 20 | 7376 | 13820 | 90607231 |
| Sudden onset of sleep | 38.21 | 18.99 | 9 | 7387 | 576 | 90620475 |
| Neuroleptic malignant syndrome | 37.00 | 18.99 | 20 | 7376 | 15076 | 90605975 |
| Depressed level of consciousness | 36.69 | 18.99 | 37 | 7359 | 72747 | 90548304 |
| Wrong product administered | 36.51 | 18.99 | 16 | 7380 | 7649 | 90613402 |
| Subileus | 36.42 | 18.99 | 13 | 7383 | 3631 | 90617420 |
| Agitation | 35.46 | 18.99 | 35 | 7361 | 67063 | 90553988 |
| Faecaloma | 34.77 | 18.99 | 17 | 7379 | 10414 | 90610637 |
| Gastrointestinal sounds abnormal | 33.63 | 18.99 | 13 | 7383 | 4530 | 90616521 |
| Tarsal tunnel syndrome | 33.13 | 18.99 | 8 | 7388 | 569 | 90620482 |
| Somnolence | 32.63 | 18.99 | 60 | 7336 | 209024 | 90412027 |
| Purpura senile | 32.63 | 18.99 | 8 | 7388 | 607 | 90620444 |
| Off label use | 31.96 | 18.99 | 26 | 7370 | 1102226 | 89518825 |
| Resorption bone increased | 31.65 | 18.99 | 9 | 7387 | 1210 | 90619841 |
| Compulsive shopping | 30.85 | 18.99 | 8 | 7388 | 761 | 90620290 |
| Renal failure | 30.45 | 18.99 | 45 | 7351 | 130962 | 90490089 |
| Speech disorder | 30.27 | 18.99 | 27 | 7369 | 45558 | 90575493 |
| Disorientation | 29.04 | 18.99 | 26 | 7370 | 44088 | 90576963 |
| Impulse-control disorder | 28.91 | 18.99 | 8 | 7388 | 974 | 90620077 |
| Blood creatine phosphokinase increased | 28.43 | 18.99 | 23 | 7373 | 34000 | 90587051 |
| Dysphagia | 28.18 | 18.99 | 40 | 7356 | 112238 | 90508813 |
| Freezing phenomenon | 28.13 | 18.99 | 9 | 7387 | 1803 | 90619248 |
| Delirium | 27.41 | 18.99 | 38 | 7358 | 104321 | 90516730 |
| Movement disorder | 27.22 | 18.99 | 21 | 7375 | 28998 | 90592053 |
| Aggression | 26.56 | 18.99 | 20 | 7376 | 26648 | 90594403 |
| Psychotic disorder | 25.86 | 18.99 | 21 | 7375 | 31209 | 90589842 |
| Gait disturbance | 25.74 | 18.99 | 62 | 7334 | 260434 | 90360617 |
| Vestibular disorder | 25.31 | 18.99 | 8 | 7388 | 1541 | 90619510 |
| Alopecia | 25.04 | 18.99 | 5 | 7391 | 495066 | 90125985 |
| Abdominal tenderness | 24.67 | 18.99 | 13 | 7383 | 9311 | 90611740 |
| Coronary artery dissection | 24.57 | 18.99 | 7 | 7389 | 947 | 90620104 |
| Joint swelling | 23.62 | 18.99 | 6 | 7390 | 503294 | 90117757 |
| Bradykinesia | 22.44 | 18.99 | 11 | 7385 | 6777 | 90614274 |
| Product administration error | 22.37 | 18.99 | 18 | 7378 | 26405 | 90594646 |
| On and off phenomenon | 21.43 | 18.99 | 8 | 7388 | 2535 | 90618516 |
| Peripheral swelling | 21.25 | 18.99 | 4 | 7392 | 413102 | 90207949 |
| Application site reaction | 20.97 | 18.99 | 6 | 7390 | 824 | 90620227 |
| Syncope | 20.59 | 18.99 | 38 | 7358 | 132625 | 90488426 |
| Tricuspid valve incompetence | 19.96 | 18.99 | 14 | 7382 | 16717 | 90604334 |
| Stereotypy | 19.54 | 18.99 | 5 | 7391 | 451 | 90620600 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Parkinson's disease | 236.90 | 16.73 | 54 | 7976 | 1268 | 42612037 |
| Hallucination | 212.28 | 16.73 | 133 | 7897 | 57374 | 42555931 |
| Gambling disorder | 185.88 | 16.73 | 47 | 7983 | 1729 | 42611576 |
| Hypersexuality | 153.47 | 16.73 | 40 | 7990 | 1662 | 42611643 |
| Hallucination, visual | 129.55 | 16.73 | 68 | 7962 | 20952 | 42592353 |
| Muscle rigidity | 129.14 | 16.73 | 57 | 7973 | 12002 | 42601303 |
| Dyskinesia | 114.87 | 16.73 | 67 | 7963 | 25323 | 42587982 |
| Fall | 106.98 | 16.73 | 172 | 7858 | 234348 | 42378957 |
| Confusional state | 89.02 | 16.73 | 132 | 7898 | 167465 | 42445840 |
| On and off phenomenon | 85.52 | 16.73 | 30 | 8000 | 3437 | 42609868 |
| Sudden onset of sleep | 69.66 | 16.73 | 16 | 8014 | 388 | 42612917 |
| Agitation | 68.65 | 16.73 | 72 | 7958 | 64242 | 42549063 |
| Neuroleptic malignant syndrome | 65.16 | 16.73 | 44 | 7986 | 21428 | 42591877 |
| Gambling | 62.26 | 16.73 | 13 | 8017 | 199 | 42613106 |
| Orthostatic hypotension | 61.78 | 16.73 | 49 | 7981 | 30521 | 42582784 |
| Delusion | 61.68 | 16.73 | 37 | 7993 | 14697 | 42598608 |
| Abnormal behaviour | 61.32 | 16.73 | 46 | 7984 | 26405 | 42586900 |
| Somnolence | 56.76 | 16.73 | 98 | 7932 | 141007 | 42472298 |
| Dopamine dysregulation syndrome | 54.23 | 16.73 | 14 | 8016 | 559 | 42612746 |
| Tremor | 52.28 | 16.73 | 77 | 7953 | 96852 | 42516453 |
| Psychotic disorder | 51.00 | 16.73 | 43 | 7987 | 29165 | 42584140 |
| Aggression | 49.90 | 16.73 | 51 | 7979 | 44112 | 42569193 |
| Off label use | 45.07 | 16.73 | 33 | 7997 | 638302 | 41975003 |
| Impulse-control disorder | 44.16 | 16.73 | 15 | 8015 | 1560 | 42611745 |
| Bradykinesia | 43.48 | 16.73 | 21 | 8009 | 5415 | 42607890 |
| Dementia | 36.72 | 16.73 | 28 | 8002 | 16452 | 42596853 |
| Dysphagia | 36.66 | 16.73 | 56 | 7974 | 72663 | 42540642 |
| Product complaint | 35.83 | 16.73 | 19 | 8011 | 5958 | 42607347 |
| Supine hypertension | 34.47 | 16.73 | 9 | 8021 | 376 | 42612929 |
| Gait disturbance | 34.15 | 16.73 | 64 | 7966 | 97936 | 42515369 |
| Parkinsonism | 32.77 | 16.73 | 22 | 8008 | 10601 | 42602704 |
| Disorientation | 32.29 | 16.73 | 37 | 7993 | 36352 | 42576953 |
| Delirium | 31.62 | 16.73 | 44 | 7986 | 52475 | 42560830 |
| Aortic valve incompetence | 31.50 | 16.73 | 18 | 8012 | 6530 | 42606775 |
| Obsessive-compulsive disorder | 31.01 | 16.73 | 18 | 8012 | 6725 | 42606580 |
| Syncope | 29.87 | 16.73 | 61 | 7969 | 99345 | 42513960 |
| Libido increased | 26.19 | 16.73 | 9 | 8021 | 969 | 42612336 |
| Diarrhoea | 22.08 | 16.73 | 33 | 7997 | 460816 | 42152489 |
| Mania | 21.49 | 16.73 | 17 | 8013 | 10530 | 42602775 |
| Akinesia | 21.14 | 16.73 | 10 | 8020 | 2462 | 42610843 |
| Mesenteric artery thrombosis | 20.61 | 16.73 | 7 | 8023 | 727 | 42612578 |
| Obsessive-compulsive personality disorder | 20.47 | 16.73 | 5 | 8025 | 159 | 42613146 |
| Persecutory delusion | 20.44 | 16.73 | 11 | 8019 | 3553 | 42609752 |
| Micrographia | 19.44 | 16.73 | 3 | 8027 | 6 | 42613299 |
| Delusion of replacement | 18.90 | 16.73 | 5 | 8025 | 220 | 42613085 |
| Compulsions | 18.45 | 16.73 | 5 | 8025 | 241 | 42613064 |
| Soft tissue mass | 18.42 | 16.73 | 7 | 8023 | 1005 | 42612300 |
| Restlessness | 18.34 | 16.73 | 25 | 8005 | 29224 | 42584081 |
| Illusion | 18.30 | 16.73 | 7 | 8023 | 1022 | 42612283 |
| Posture abnormal | 17.96 | 16.73 | 9 | 8021 | 2512 | 42610793 |
| Mental status changes | 17.86 | 16.73 | 30 | 8000 | 42085 | 42571220 |
| Serotonin syndrome | 17.60 | 16.73 | 23 | 8007 | 25822 | 42587483 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hallucination | 319.48 | 16.79 | 174 | 11752 | 101258 | 110476115 |
| Parkinson's disease | 299.64 | 16.79 | 61 | 11865 | 1478 | 110575895 |
| Dyskinesia | 221.59 | 16.79 | 109 | 11817 | 51337 | 110526036 |
| Hallucination, visual | 191.96 | 16.79 | 91 | 11835 | 39514 | 110537859 |
| Muscle rigidity | 150.43 | 16.79 | 66 | 11860 | 23965 | 110553408 |
| Hypersexuality | 134.27 | 16.79 | 33 | 11893 | 1907 | 110575466 |
| Gambling disorder | 125.35 | 16.79 | 32 | 11894 | 2159 | 110575214 |
| Fall | 121.53 | 16.79 | 226 | 11700 | 603256 | 109974117 |
| Tremor | 112.01 | 16.79 | 123 | 11803 | 202109 | 110375264 |
| Agitation | 106.40 | 16.79 | 92 | 11834 | 112959 | 110464414 |
| Confusional state | 103.74 | 16.79 | 183 | 11743 | 468497 | 110108876 |
| On and off phenomenon | 103.10 | 16.79 | 32 | 11894 | 4392 | 110572981 |
| Neuroleptic malignant syndrome | 103.09 | 16.79 | 57 | 11869 | 34002 | 110543371 |
| Delusion | 80.91 | 16.79 | 43 | 11883 | 23712 | 110553661 |
| Abnormal behaviour | 80.52 | 16.79 | 51 | 11875 | 38988 | 110538385 |
| Orthostatic hypotension | 77.08 | 16.79 | 61 | 11865 | 66188 | 110511185 |
| Aortic valve incompetence | 74.72 | 16.79 | 32 | 11894 | 10949 | 110566424 |
| Aggression | 72.09 | 16.79 | 56 | 11870 | 59154 | 110518219 |
| Dementia | 71.94 | 16.79 | 44 | 11882 | 31629 | 110545744 |
| Somnolence | 69.40 | 16.79 | 119 | 11807 | 297330 | 110280043 |
| Dopamine dysregulation syndrome | 66.11 | 16.79 | 15 | 11911 | 612 | 110576761 |
| Bradykinesia | 62.26 | 16.79 | 28 | 11898 | 10760 | 110566613 |
| Parkinsonism | 61.34 | 16.79 | 35 | 11891 | 22152 | 110555221 |
| Off label use | 59.78 | 16.79 | 45 | 11881 | 1500140 | 109077233 |
| Psychotic disorder | 55.20 | 16.79 | 45 | 11881 | 50892 | 110526481 |
| Product complaint | 52.45 | 16.79 | 27 | 11899 | 13945 | 110563428 |
| Vascular encephalopathy | 51.91 | 16.79 | 13 | 11913 | 811 | 110576562 |
| Disorientation | 51.75 | 16.79 | 50 | 11876 | 70621 | 110506752 |
| Drug interaction | 51.68 | 16.79 | 144 | 11782 | 500039 | 110077334 |
| Impulse-control disorder | 51.67 | 16.79 | 16 | 11910 | 2178 | 110575195 |
| Ileus | 48.51 | 16.79 | 34 | 11892 | 30695 | 110546678 |
| Delirium | 45.42 | 16.79 | 64 | 11862 | 134961 | 110442412 |
| Gambling | 45.23 | 16.79 | 10 | 11916 | 362 | 110577011 |
| Syncope | 44.54 | 16.79 | 79 | 11847 | 202457 | 110374916 |
| Sudden onset of sleep | 43.76 | 16.79 | 11 | 11915 | 697 | 110576676 |
| Tricuspid valve incompetence | 41.43 | 16.79 | 28 | 11898 | 23845 | 110553528 |
| Gait disturbance | 41.25 | 16.79 | 92 | 11834 | 278116 | 110299257 |
| Dysphagia | 39.16 | 16.79 | 64 | 11862 | 153536 | 110423837 |
| Speech disorder | 34.97 | 16.79 | 38 | 11888 | 61531 | 110515842 |
| Depressed level of consciousness | 34.51 | 16.79 | 51 | 11875 | 112227 | 110465146 |
| Mitral valve incompetence | 33.10 | 16.79 | 28 | 11898 | 33301 | 110544072 |
| Supine hypertension | 32.87 | 16.79 | 8 | 11918 | 443 | 110576930 |
| Akinesia | 32.81 | 16.79 | 13 | 11913 | 3654 | 110573719 |
| Tarsal tunnel syndrome | 31.31 | 16.79 | 8 | 11918 | 541 | 110576832 |
| Blood creatine phosphokinase increased | 31.29 | 16.79 | 39 | 11887 | 73038 | 110504335 |
| Dystonia | 30.51 | 16.79 | 24 | 11902 | 25781 | 110551592 |
| Purpura senile | 30.41 | 16.79 | 8 | 11918 | 607 | 110576766 |
| Diarrhoea | 30 | 16.79 | 48 | 11878 | 1139457 | 109437916 |
| Granulocytopenia | 29.73 | 16.79 | 18 | 11908 | 12697 | 110564676 |
| Faecaloma | 29.54 | 16.79 | 19 | 11907 | 14889 | 110562484 |
| Subileus | 28.76 | 16.79 | 14 | 11912 | 6423 | 110570950 |
| Serotonin syndrome | 27.64 | 16.79 | 33 | 11893 | 59120 | 110518253 |
| Posture abnormal | 27.15 | 16.79 | 12 | 11914 | 4426 | 110572947 |
| Resorption bone increased | 27.14 | 16.79 | 9 | 11917 | 1525 | 110575848 |
| Abnormal dreams | 27.10 | 16.79 | 17 | 11909 | 12763 | 110564610 |
| Movement disorder | 27.10 | 16.79 | 26 | 11900 | 36378 | 110540995 |
| Gastrointestinal sounds abnormal | 26.62 | 16.79 | 13 | 11913 | 6005 | 110571368 |
| Deep brain stimulation | 26.40 | 16.79 | 5 | 11921 | 82 | 110577291 |
| Dementia with Lewy bodies | 26.06 | 16.79 | 8 | 11918 | 1058 | 110576315 |
| Mental status changes | 25.46 | 16.79 | 36 | 11890 | 76086 | 110501287 |
| Obsessive-compulsive disorder | 24.35 | 16.79 | 13 | 11913 | 7228 | 110570145 |
| Hepatic enzyme increased | 24.31 | 16.79 | 3 | 11923 | 320889 | 110256484 |
| Obsessive-compulsive personality disorder | 24.14 | 16.79 | 5 | 11921 | 132 | 110577241 |
| Urticaria | 24.11 | 16.79 | 3 | 11923 | 318854 | 110258519 |
| Peripheral swelling | 23.83 | 16.79 | 7 | 11919 | 404027 | 110173346 |
| Dysstasia | 23.50 | 16.79 | 23 | 11903 | 32963 | 110544410 |
| Pain | 23.47 | 16.79 | 42 | 11884 | 954913 | 109622460 |
| Compulsive shopping | 23.30 | 16.79 | 7 | 11919 | 861 | 110576512 |
| International normalised ratio increased | 23.26 | 16.79 | 37 | 11889 | 86735 | 110490638 |
| Persecutory delusion | 23.16 | 16.79 | 12 | 11914 | 6279 | 110571094 |
| Mesenteric artery thrombosis | 22.65 | 16.79 | 7 | 11919 | 946 | 110576427 |
| Product use in unapproved indication | 22.57 | 16.79 | 10 | 11916 | 447367 | 110130006 |
| Freezing phenomenon | 22.47 | 16.79 | 9 | 11917 | 2600 | 110574773 |
| Drug intolerance | 22.28 | 16.79 | 8 | 11918 | 406504 | 110170869 |
| Alopecia | 22.10 | 16.79 | 6 | 11920 | 364747 | 110212626 |
| Mania | 21.74 | 16.79 | 18 | 11908 | 20778 | 110556595 |
| Cerebral atrophy | 21.60 | 16.79 | 13 | 11913 | 9072 | 110568301 |
| Aortic valve sclerosis | 21.51 | 16.79 | 8 | 11918 | 1895 | 110575478 |
| Balance disorder | 21.27 | 16.79 | 42 | 11884 | 116518 | 110460855 |
| Autonomic nervous system imbalance | 21.20 | 16.79 | 11 | 11915 | 5769 | 110571604 |
| Product use issue | 21.14 | 16.79 | 4 | 11922 | 311691 | 110265682 |
| Illusion | 21.10 | 16.79 | 8 | 11918 | 1999 | 110575374 |
| Coronary artery dissection | 20.80 | 16.79 | 7 | 11919 | 1241 | 110576132 |
| Joint swelling | 20.66 | 16.79 | 11 | 11915 | 442834 | 110134539 |
| Delusion of replacement | 20.65 | 16.79 | 5 | 11921 | 271 | 110577102 |
| Chorea | 20.61 | 16.79 | 9 | 11917 | 3226 | 110574147 |
| Death | 20.40 | 16.79 | 137 | 11789 | 698732 | 109878641 |
| Abdominal tenderness | 20.16 | 16.79 | 14 | 11912 | 12443 | 110564930 |
| Drug hypersensitivity | 20.15 | 16.79 | 12 | 11914 | 454078 | 110123295 |
| Mitral valve disease | 20.11 | 16.79 | 9 | 11917 | 3416 | 110573957 |
| Treatment failure | 20.03 | 16.79 | 3 | 11923 | 277231 | 110300142 |
| Dysarthria | 20.02 | 16.79 | 34 | 11892 | 84087 | 110493286 |
| Sinusitis | 19.71 | 16.79 | 4 | 11922 | 296684 | 110280689 |
| Reduced facial expression | 19.56 | 16.79 | 9 | 11917 | 3642 | 110573731 |
| Intermittent claudication | 19.44 | 16.79 | 9 | 11917 | 3692 | 110573681 |
| Soft tissue mass | 19.39 | 16.79 | 7 | 11919 | 1526 | 110575847 |
| Dizziness | 19.27 | 16.79 | 135 | 11791 | 698058 | 109879315 |
| Sudden death | 19.26 | 16.79 | 18 | 11908 | 24377 | 110552996 |
| Vestibular disorder | 19.00 | 16.79 | 8 | 11918 | 2624 | 110574749 |
| Pneumonia aspiration | 18.24 | 16.79 | 32 | 11894 | 81201 | 110496172 |
| Restlessness | 17.92 | 16.79 | 26 | 11900 | 56233 | 110521140 |
| Febrile neutropenia | 17.76 | 16.79 | 6 | 11920 | 316761 | 110260612 |
| Urinary retention | 17.70 | 16.79 | 29 | 11897 | 69654 | 110507719 |
| Feeling abnormal | 17.59 | 16.79 | 51 | 11875 | 180660 | 110396713 |
| Stomatitis | 17.23 | 16.79 | 4 | 11922 | 270238 | 110307135 |
| Hallucinations, mixed | 17.03 | 16.79 | 11 | 11915 | 8682 | 110568691 |
| COVID-19 | 16.92 | 16.79 | 3 | 11923 | 245057 | 110332316 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:48560 | dopaminergic agent |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
| CHEBI has role | CHEBI:59321 | EC 4.1.1.28 (aromatic-<small>L</small>-amino-acid decarboxylase) inhibitor |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:66956 | antidyskinesia agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:73336 | vulnerary |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| MeSH PA | D065105 | Aromatic Amino Acid Decarboxylase Inhibitors |
| FDA EPC | N0000175754 | Aromatic Amino Acid Decarboxylation Inhibitor |
| FDA MoA | N0000175755 | DOPA Decarboxylase Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postencephalitic parkinsonism | indication | 19972008 | DOID:14332 |
| Parkinsonism | indication | 32798002 | |
| Parkinson's disease | indication | 49049000 | DOID:14330 |
| Restless legs | off-label use | 32914008 | DOID:0050425 |
| Suicidal thoughts | contraindication | 6471006 | |
| Hallucinations | contraindication | 7011001 | |
| Dyskinesia | contraindication | 9748009 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Obstruction of bile duct | contraindication | 30144000 | |
| Depressive disorder | contraindication | 35489007 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Duodenal ulcer disease | contraindication | 51868009 | DOID:1724 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Diarrhea | contraindication | 62315008 | |
| Psychotic disorder | contraindication | 69322001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Cataract surgery | contraindication | 110473004 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Seizure disorder | contraindication | 128613002 | |
| Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Retention of urine | contraindication | 267064002 | |
| Psychoneurotic personality disorder | contraindication | 268634009 | |
| Malignant melanoma | contraindication | 372244006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Cardiovascular event risk | contraindication | 395112001 | |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Intraoperative floppy iris syndrome | contraindication | 418801006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.4 | acidic |
| pKa2 | 10.49 | acidic |
| pKa3 | 13.92 | acidic |
| pKa4 | 7.18 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 23.75MG;95MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 36.25MG;145MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 48.75MG;195MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8377474 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8454998 | Dec. 26, 2028 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8557283 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9089607 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9463246 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9533046 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 61.25MG;245MG | RYTARY | IMPAX | N203312 | Jan. 7, 2015 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9901640 | Dec. 26, 2028 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10098845 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292935 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10688058 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10973769 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10987313 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11666538 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12128141 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12178919 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10098845 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292935 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10688058 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10973769 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10987313 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11666538 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12128141 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12178919 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10098845 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292935 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10688058 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10973769 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10987313 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11666538 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12128141 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12178919 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10098845 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292935 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10688058 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10973769 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10987313 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11666538 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12128141 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12178919 | Oct. 7, 2034 | TREATMENT OF PARKINSONS DISEASE |
| 25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11033521 | March 28, 2039 | METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG |
| 25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11033521 | March 28, 2039 | METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG, EACH SEGMENT HAVING CARBIDOPA—6.25 MG/LEVODOPA—25 MG |
| 25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11033521 | March 28, 2039 | TREATMENT OF PARKINSONS DISEASE |
| 25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11439613 | March 28, 2039 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 25MG;100MG | DHIVY | AVION PHARMS | N214869 | Nov. 12, 2021 | RX | TABLET | ORAL | 11819485 | March 28, 2039 | TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11986449 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12194150 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11986449 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12194150 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11986449 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12194150 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11986449 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12109185 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12194150 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12201596 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263148 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12263149 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12295931 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303481 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12303482 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12370163 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12447139 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12453710 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF PARKINSONS DISEASE |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 12458616 | Dec. 21, 2041 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 35MG;140MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Aug. 7, 2027 | NEW PRODUCT |
| 52.5MG;210MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Aug. 7, 2027 | NEW PRODUCT |
| 70MG;280MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Aug. 7, 2027 | NEW PRODUCT |
| 87.5MG;350MG | CREXONT | IMPAX | N217186 | Aug. 7, 2024 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Aug. 7, 2027 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Aromatic-L-amino-acid decarboxylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 5.17 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.43 | DRUG MATRIX | |||||
| Lysine-specific demethylase 4E | Enzyme | Ki | 5.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017949 | VUID |
| N0000146299 | NUI |
| D00558 | KEGG_DRUG |
| 38821-49-7 | SECONDARY_CAS_RN |
| 2019 | RXNORM |
| C0006982 | UMLSCUI |
| CHEBI:3395 | CHEBI |
| 142 | PDB_CHEM_ID |
| CHEMBL1200748 | ChEMBL_ID |
| DB00190 | DRUGBANK_ID |
| D002230 | MESH_DESCRIPTOR_UI |
| 34359 | PUBCHEM_CID |
| 5159 | IUPHAR_LIGAND_ID |
| 31531 | MMSL |
| 4355 | MMSL |
| 71847 | MMSL |
| d00184 | MMSL |
| 386107009 | SNOMEDCT_US |
| 73579000 | SNOMEDCT_US |
| 4017949 | VANDF |
| MNX7R8C5VO | UNII |
| 001085 | NDDF |
| MNX7R8C5VO | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Duopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-3012 | SUSPENSION | 4.63 mg | ENTERAL | NDA | 31 sections |
| Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9701 | TABLET | 10 mg | ORAL | ANDA | 11 sections |
| Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9702 | TABLET | 25 mg | ORAL | ANDA | 11 sections |
| Carbidopa and levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-9703 | TABLET | 25 mg | ORAL | ANDA | 11 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0088 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 24 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-0094 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 24 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-8460 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 27 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-8461 | TABLET, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 27 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-8516 | TABLET | 25 mg | ORAL | ANDA | 25 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-8536 | TABLET | 25 mg | ORAL | ANDA | 25 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0615-8555 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
| Carbidopa, Levodopa, and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-5613 | TABLET, FILM COATED | 12.50 mg | ORAL | NDA authorized generic | 26 sections |
| Carbidopa, Levodopa, and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-5625 | TABLET, FILM COATED | 18.75 mg | ORAL | NDA authorized generic | 26 sections |
| Carbidopa, Levodopa, and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-5637 | TABLET, FILM COATED | 25 mg | ORAL | NDA authorized generic | 26 sections |
| Carbidopa, Levodopa, and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-5641 | TABLET, FILM COATED | 31.25 mg | ORAL | NDA authorized generic | 26 sections |
| Carbidopa, Levodopa, and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-5654 | TABLET, FILM COATED | 37.50 mg | ORAL | NDA authorized generic | 26 sections |
| Carbidopa, Levodopa, and Entacapone | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0781-5669 | TABLET, FILM COATED | 50 mg | ORAL | NDA authorized generic | 26 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0904-7501 | TABLET | 25 mg | ORAL | ANDA | 25 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0904-7549 | TABLET | 25 mg | ORAL | ANDA | 25 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16571-157 | TABLET, ORALLY DISINTEGRATING | 10 mg | ORAL | ANDA | 24 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16571-158 | TABLET, ORALLY DISINTEGRATING | 25 mg | ORAL | ANDA | 24 sections |
| Carbidopa and Levodopa | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16571-159 | TABLET, ORALLY DISINTEGRATING | 25 mg | ORAL | ANDA | 24 sections |
| CARBIDOPA, LEVODOPA AND ENTACAPONE | Human Prescription Drug Label | 3 | 16571-689 | TABLET, FILM COATED | 12.50 mg | ORAL | ANDA | 27 sections |
| CARBIDOPA, LEVODOPA AND ENTACAPONE | Human Prescription Drug Label | 3 | 16571-690 | TABLET, FILM COATED | 18.75 mg | ORAL | ANDA | 27 sections |
| CARBIDOPA, LEVODOPA AND ENTACAPONE | Human Prescription Drug Label | 3 | 16571-691 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 27 sections |
| CARBIDOPA, LEVODOPA AND ENTACAPONE | Human Prescription Drug Label | 3 | 16571-692 | TABLET, FILM COATED | 31.25 mg | ORAL | ANDA | 27 sections |
| CARBIDOPA, LEVODOPA AND ENTACAPONE | Human Prescription Drug Label | 3 | 16571-693 | TABLET, FILM COATED | 37.50 mg | ORAL | ANDA | 27 sections |
| CARBIDOPA, LEVODOPA AND ENTACAPONE | Human Prescription Drug Label | 3 | 16571-694 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 27 sections |
| Carbidopa | Human Prescription Drug Label | 1 | 16714-067 | TABLET | 25 mg | ORAL | ANDA | 23 sections |
| CARBIDOPA AND LEVODOPA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16729-078 | TABLET, EXTENDED RELEASE | 25 mg | ORAL | ANDA | 27 sections |